St Jude modifies HF (heart failure) device study:
This article was originally published in Clinica
Executive Summary
The US FDA has given St Jude Medical permission to reduce the required sample size in a trial of its cardiac resynchronisation device for treating heart failure (HF) patients who are also at risk of dangerously fast heart rhythms. The study, called RHYTHM, will now require six-month follow-up data on a minimum of 126 patients implanted with St Jude's Epic HF Model V-338 ICD, as opposed to 276 patients. The St Paul, Minnesota firm said it expected to complete the enrolment phase of study in early 2003 and to receive US regulatory approval of the device in early 2004.
You may also be interested in...
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.